Pfizer Taps Avant’s Phase II Brain Cancer Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Therapeutic vaccine is a “beautiful” match with temozolomide, Avant CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.
Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in